Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme Therapeutics's quarterly market cap
declined
from Dec. 2025 (MXN144,401 Mil) to Mar. 2026 (MXN139,502 Mil) but then
increased
from Mar. 2026 (MXN139,502 Mil) to Jun. 2026 (MXN151,334 Mil).
Halozyme Therapeutics's annual market cap
declined
from Dec. 2023 (MXN86,204 Mil) to Dec. 2024 (MXN83,734 Mil) but then
increased
from Dec. 2024 (MXN83,734 Mil) to Dec. 2025 (MXN144,401 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Halozyme Therapeutics's Enterprise Value for Today is MXN241,129 Mil.
Halozyme Therapeutics (MEX:HALO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HALO vs NUVL, KRYS, IONS: Market Cap Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Halozyme Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (MEX:HALO) has a Market Cap of MXN208,439 Mil as of Aug. 20, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Halozyme Therapeutics and its competitors. According to the industry distribution chart, Halozyme Therapeutics ranks #32 out of 1422 companies in the Biotechnology industry, placing it in the top 2.3%.
Is Halozyme Therapeutics' Market Cap too high?
Halozyme Therapeutics' current Market Cap is MXN208,439 Mil. Based on the distribution chart, Halozyme Therapeutics ranks #32 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Market Cap compare to NUVL and KRYS?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #32 out of 1422 companies for Market Cap. This places Halozyme Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.46, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 121.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Market Cap is MXN208,439 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (MEX:HALO) is currently considered Fairly Valued. The stock's GF Value™ is MXN1,579.10, compared to a current price of MXN1,740.00 — trading 10.2% above its estimated fair value. The current Market Cap is MXN208,439 Mil. Halozyme Therapeutics' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Halozyme Therapeutics (MEX:HALO), the current Market Cap is MXN208,439 Mil as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (MEX:HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued.
The current stock price of MXN1,740.00 is trading 10.2% above its estimated GF Value™ of MXN1,579.10.
GuruFocus considers Halozyme Therapeutics to be Fairly Valued.
Key valuation signals for MEX:HALO:
Market Cap: MXN208,439 Mil
GF Value™: MXN1,579.10 vs. price of MXN1,740.00 (10.2% above fair value)
No single metric tells the full story. See the MEX:HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
89GF Score
Get the complete analysis for MEX:HALO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HALO has been successfully added to your 
